The DOI matches its OpenAlex record; 22 of the 22 references it cites were found in a registry or an index.
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Published version of a preprint
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
Self-citationStructural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
Distinct conformational states of SARS-CoV-2 spike protein
Cai, Y., Zhang, J., Xiao, T., Peng, H., Sterling, S. M., Walsh, R. M., Rawson, S., Rits-Volloch, S., & Chen, B. (2020) · Science · doi:10.1126/science.abd4251 · Cited by 1,221
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & Balicer, R. D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02249-2 · Cited by 860
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743
Neutralizing monoclonal antibodies for treatment of COVID-19
Taylor, P. C., Adams, A. C., Hufford, M. M., de la Torre, I., Winthrop, K., & Gottlieb, R. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00542-x · Cited by 732
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03696-9 · Cited by 721
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Self-citationAntibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101667 · Cited by 696
Syncytia formation by SARS‐CoV‐2‐infected cells
Buchrieser, J., Dufloo, J., Hubert, M., Monel, B., Planas, D., Rajah, M. M., Planchais, C., Porrot, F., Guivel‐Benhassine, F., Van der Werf, S., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106267 · Cited by 462
Self-citationSARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · Science · doi:10.1126/science.abi7994 · Cited by 412
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gehlhausen, J. R., Campbell, M., Silva, J., Tabachnikova, A., et al. (2021) · Nature · doi:10.1038/s41586-021-04085-y · Cited by 226
Research works printed but not linked: 22
- Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398, 2126–2128 (2021). · DOI · Paper page
- Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, https://doi.org/10.1038/s41586-022-04411-y (2022). · DOI · Paper page
- Grabowski, F., Kochańczyk, M. & Lipniacki, T. Omicron strain spreads with the doubling time of 3.2–3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant. Preprint at https://doi.org/10.1101/2021.12.08.21267494 (2021). · DOI
- Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature, https://doi.org/10.1038/s41586-021-04387-1 (2021). · doi:10.1038/s41586-021-04387-1 · Paper page
- Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, https://doi.org/10.1038/s41586-021-04386-2 (2021). · DOI · Paper page
- Dejnirattisai, W. et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236 (2021). · DOI · Paper page
- Aggarwal, A. et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. Preprint at https://doi.org/10.1101/2021.12.14.21267772 (2021). · doi:10.1101/2021.12.14.21267772
- Redd, A. D. et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. Preprint at https://doi.org/10.1101/2021.12.06.471446 (2021). · DOI
- Rajah, M. M. et al. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced spike-mediated syncytia formation. EMBO J. 40, e108944 (2021). · DOI · Paper page
- Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823–829 (2021). · DOI · Paper page
- Kim, C. et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat. Commun. 12, 288 (2021). · DOI · Paper page
- Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. 13, eabf1906 (2021). · DOI · Paper page
- Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020). · DOI · Paper page
- Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021). · DOI · Paper page
- Gallais, F. et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection,EBioMedicine 71, 103561 (2021). · DOI · Paper page
- Plante, J. A. et al. The variant gambit: COVID-19’s next move. Cell Host Microbe 29, 508–515 (2021). · DOI · Paper page
- Gagne, M. et al. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques is coincident with anamnestic antibody response in the lung. Cell 185, 113–130 (2021). · DOI
- Tzou, P. L. et al. Coronavirus Antiviral Research Database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds. Viruses 12, 1006 (2020). · DOI
- Van Cleemput, J. et al. Organ-specific genome diversity of replication-competent SARS-CoV-2. Nat. Commun. 12, 6612 (2021). · DOI
- Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112–124 (2008). · DOI · Paper page
- Lorin, V. & Mouquet, H. Efficient generation of human IgA monoclonal antibodies. J. Immunol. Methods 422, 102–110 (2015). · DOI
- Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020). · doi:10.1016/j.cell.2020.02.058 · Paper page
Cited by
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F.-W., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04594-4 · Cited by 809
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
Keeton, R., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M., Karim, F., et al. (2022) · Nature · doi:10.1038/s41586-022-04460-3 · Cited by 633
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380
Metadata
- Authors
- Planas, D., Saunders, N., Maes, P., Guivel‐Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W., Porrot, F., Staropoli, I., Lemoine, F., Péré, H., Veyer, D. L., Puech, J., Rodary, J., Baela, G., Dellicour, S., Raymenants, J., Gorissen, S., Geenen, C., Vanmechelen, B., Wawina-Bokalanga, T., Martí‐Carreras, J., Cuypers, L., Sève, A., Hocqueloux, L., Prazuck, T., Rey, F. A., Simon‐Lorière, E., Bruel, T., Mouquet, H., André, E., & Schwartz, O.
- Venue
- Nature
- Published
- 2021-12-23
- Volume
- 602
- Issue
- 7898
- Pages
- 671-675
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4200026982
- Cited by
- 197
- References
- 22
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.